Female Genital Schistosomiasis: Addressing Diagnostic and Programmatic Gaps to Advance Elimination Efforts

Highlights

• Gaps in knowledge, diagnostics, and program implementation of FGS

• Case studies on various approaches to address integration in addressing FGS

• Multi-sectoral partnerships that align health initiatives to FGS as morbidity

Abstract

This report underscores the critical need to include Female Genital Schistosomiasis (FGS) within schistosomiasis elimination frameworks and sexual and reproductive health programs. Affecting an estimated 40–56 million women, mainly in sub-Saharan Africa, FGS is often underdiagnosed and neglected in public health programs. This paper highlights FGS as a vital gap in schistosomiasis control and comprehensive sexual and reproductive health services, advocating for integrated approaches that address FGS awareness and diagnosis within disease elimination initiatives and health services. Enhanced diagnostic and treatment capabilities for FGS in endemic regions are essential to alleviate the physical, psychological, and reproductive health impacts on affected women and to advance global schistosomiasis elimination goals.